REGN has a Zacks Rank #1 (Strong Buy) with positive earnings estimate revisions, forward P/E of 14.16, PEG ratio of 1.23, P/B ratio of 2.44, and a Value grade of B, making it more attractive for value investors compared to its peer.
The company demonstrated strong recent fundamentals with 17% YoY revenue growth, exceptional drug sales (Dupixent +38%, Libtayo +30%, Eylea HD +52%), a robust pipeline of 50 product candidates, and an attractive valuation (19x trailing earnings vs. S&P 500's 23x). The stock reached a 52-week high in early September and is positioned for potential further gains following Q3 earnings.
Strong Q2 revenue growth of 17%, successful Dupixent sales growth of 38%, effective mitigation of Eylea decline through HD formulation, and promising pipeline candidates like olatorepatide position the company well despite recent stock underperformance and competitive pressures.
The company faces a securities class action lawsuit alleging it made false and misleading statements about a failed Phase 3 clinical trial, concealed critical information about slow event rates and flawed statistical assumptions, and altered trial protocols without timely disclosure to investors. The trial failure resulted in an $11 billion market capitalization loss.
The company is accused of making materially false and misleading statements about a critical Phase III clinical trial, including flawed statistical assumptions, lack of clinical differentiation, and unlikely achievement of primary endpoints. These allegations suggest potential fraud and significant clinical/commercial setbacks for a key drug candidate.
Phase II trial data demonstrates clinical efficacy of trevogrumab in preserving lean mass when combined with semaglutide, supporting continued development and potential market expansion across multiple indications including obesity, sarcopenia, and musculoskeletal disorders. Successful clinical validation could lead to broad addressable patient population and significant commercial opportunity.
The company faces securities litigation for allegedly making false and misleading statements about a failed Phase 3 clinical trial. The trial's failure resulted in an $11 billion market capitalization loss, and the lawsuit alleges management concealed critical information about flawed statistical assumptions and slow event rates while publicly expressing confidence in the trial's success.
Failed Phase III clinical trial for Fianlimab-Libtayo that did not reach statistical significance for its primary endpoint. Stock declined 6.21% on April 29, 2026, and an additional 9.82% on May 16, 2026, following disclosure of trial failure. Subject of securities fraud class action lawsuit.
Successfully rebounded from Eylea biosimilar competition with Eylea HD, strong Dupixent growth co-marketed with Sanofi, and promising weight-loss pipeline candidates. However, faces stiff competition in eye disease market from Vabysmo, patent cliff risk for Dupixent in 2031, and significant execution risk dependent on weight-loss drug success. Not recommended as the better choice.
The company faces a securities class action lawsuit alleging false and misleading statements about a failed Phase 3 clinical trial. Management allegedly concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The trial ultimately failed to meet its primary endpoint, resulting in significant shareholder losses and an $11 billion market cap decline.
The company faces a securities class action lawsuit alleging fraudulent misrepresentation regarding a failed Phase 3 clinical trial. Management allegedly concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The trial ultimately failed to meet its primary endpoint, resulting in significant shareholder losses and an $11 billion market capitalization decline.
The company is accused of making false and misleading statements about a clinical trial's likelihood of success, utilizing flawed statistical assumptions, and failing to demonstrate clinical differentiation. These allegations of securities fraud and investor losses directly harm the company's reputation and shareholder value.
The company faces securities litigation for allegedly making false and misleading statements about a failed Phase 3 clinical trial, concealing critical information about flawed statistical assumptions and lack of treatment differentiation. The trial failure resulted in an $11 billion market capitalization loss and triggered shareholder lawsuits.
The company is accused of securities fraud for misleading investors about clinical trial results. The Phase III Fianlimab-Libtayo trial failed to achieve statistical significance, leading to significant stock price declines of 6.2% and 9.8% on separate dates. A class action lawsuit has been filed against the company and its senior executives.
The company is accused of making false and misleading statements about a clinical trial's prospects, failing to disclose material risks, and ultimately announcing trial failure. The stock declined significantly (6% and then 10%) following disclosures, indicating investor loss and breach of trust.
The company faces a securities class action lawsuit for allegedly making false and misleading statements about a failed Phase 3 clinical trial, concealing critical information about flawed statistical assumptions and slow event rates. The trial failure resulted in an $11 billion market cap loss and triggered litigation from investors who suffered substantial losses.
Regeneron's participation in the private placement is a strategic investment in Parabilis' technology platform, but the article provides no information about impact on Regeneron's operations or financial position, warranting a neutral stance.
Collaborating with Sonoma Biotherapeutics on preclinical Treg cell therapy for celiac disease; involvement is early-stage preclinical, not yet in clinical development phase.
Expansion of collaboration demonstrates confidence in the combined technology approach, secures option to select up to 6 additional targets, and leverages complementary expertise in bispecific antibodies and VelociSuite technologies to advance oncology pipeline with reduced internal R&D burden.
WHO recommendation of Regeneron's maftivimab for clinical trials represents validation of the company's Ebola treatment platform and expands potential therapeutic applications beyond currently approved Zaire ebolavirus indication. The company is also demonstrating commitment to global health emergencies through supply donations and coordination with health authorities, which enhances corporate reputation and market positioning.
Regeneron is expanding its pipeline through a strategic collaboration that combines its leading antibody capabilities with a novel peptide platform to address undruggable targets. The deal demonstrates confidence in innovation and diversification of its therapeutic portfolio across multiple disease areas.
Stock declined 10.20% due to Phase 3 trial missing primary endpoint for fianlimab combination therapy despite showing numerically favorable results. The failure to achieve statistical significance represents a setback for the drug candidate and contributed to a 16.4% monthly decline and 19% year-to-date decline.
Stock tumbled 11.92% in premarket after Phase 3 trials for metastatic melanoma failed to achieve statistical significance, representing a significant setback for the company's drug development pipeline.
The Phase 3 trial failed to meet its primary endpoint of statistical significance for PFS improvement. Although a numeric improvement was observed, the failure to achieve statistical significance (p=0.0627) is a setback for the fianlimab combination therapy program and reduces the likelihood of regulatory approval for this indication.
Regeneron is highlighted as the title sponsor investing over $300 million through 2036 in premier STEM competitions (ISEF and Science Talent Search). The company demonstrates strong commitment to cultivating the next generation of scientific leaders and supporting innovation ecosystems, which enhances its corporate reputation and brand positioning in the biotech industry.
While the deal provides tariff relief and pricing certainty, the agreement requires significant price reductions on Medicaid drugs, free provision of gene therapy, and direct price alignment with international benchmarks—all of which constrain future revenue and profitability. The stock declined 2.89% at announcement, reflecting investor concerns about margin compression despite the policy certainty benefits.
Regeneron received FDA approval for a first-of-its-kind gene therapy product under an accelerated review program, representing a significant commercial and clinical achievement. The therapy addresses an unmet medical need for a rare genetic hearing loss condition, positioning the company as a leader in gene therapy innovation. This approval could open new revenue streams and strengthen the company's pipeline in genetic disease treatments.
The company secured favorable terms including tariff relief for three years, exemption from future pricing mandates, and the ability to align U.S. prices with other developed countries. While providing free gene therapy and lower prices represents some cost concessions, the agreement provides regulatory certainty and trade benefits that outweigh these costs. The company also gains positive PR from offering innovative treatments for free and demonstrates commitment to domestic manufacturing.
The approval represents successful expansion of Dupixent's commercial reach into a new pediatric patient population with limited treatment options. With over 1.4 million patients globally already on Dupixent and nine approved allergy-related indications, this approval reinforces the drug's market dominance and validates the IL-4/IL-13 inhibition mechanism across multiple disease areas.
Participated as a new investor in the Series B round, indicating confidence in Neomorph's molecular glue degrader platform and its potential to address unmet medical needs.
Stock essentially flat (up 0.07%) despite announcing a strategic partnership. While the collaboration expands Regeneron's oncology pipeline and leverages its bispecific antibody platform, the partnership is primarily beneficial to Telix as the junior partner. Limited immediate financial impact on Regeneron's large market cap.
EU approval of Dupixent for pediatric CSU represents successful regulatory milestone and commercial expansion. The approval reinforces Dupixent's position as a leading targeted therapy and expands its addressable market to younger patients, supporting continued revenue growth.
The company demonstrates solid fundamentals with strong pipeline candidates and recovery momentum (35% gain in 6 months), but the large market cap and historical performance matching the S&P 500 suggest limited potential for exceptional multimillionaire-making returns. The outlook is respectable but not exceptional.
Co-development partner receiving approval for Dupixent in a new indication in Japan. The drug's expanding approval portfolio across multiple indications and markets supports long-term growth and validates the IL-4/IL-13 inhibition mechanism across diverse type 2 inflammatory diseases.
Regeneron is extending its title sponsorship through 2036 with an additional $150 million commitment, demonstrating strong corporate investment in STEM education and talent development. The company's co-founder is a former Science Talent Search winner, showing personal commitment. This investment enhances brand reputation and supports future scientific innovation.
Mentioned only as a market report subject (Inmazeb) with no substantive content provided regarding company performance or market developments.
The article highlights two key growth drivers: Dupixent's strong market position with expanding indications providing revenue growth through early 2030s, and a robust pipeline with late-stage programs and newly approved drugs like Lynozyfic. The company has sufficient time and resources to develop new medicines before its major patent cliff, supporting above-average market returns through 2036.
Articles that tag REGN but are mainly about other companies.
Regeneron is a key player in the HoFH market with Evolocumab (REPATHA), a PCSK9 inhibitor that improves LDL receptor recycling. The expanding market and shift toward combination therapies position the company favorably for growth through 2036.
Eylea served as the comparator drug in the study. While Zenkuda showed non-inferiority and some advantages (better safety profile, dosing durability), this represents competitive pressure rather than direct negative news for Regeneron.
Mentioned as a better-ranked biotech stock (Zacks Rank #1) with improving earnings estimates, but no direct news or developments related to this company in the article.
Regeneron is mentioned as the partner in Sanofi's blockbuster Dupixent drug, which is performing exceptionally well. However, the article provides limited direct information about Regeneron's independent performance or outlook.
Featured in the list of active co-development dealmakers, indicating partnership activity, but lacking specific deal details or strategic implications.
Regeneron is mentioned as a participant in the senior leadership panel on clinical operations workforce transformation but no specific company achievements are highlighted.
Major key player in the monoclonal antibodies market positioned to benefit from 11.01% CAGR growth and expanding therapeutic applications.
Mentioned only as comparator drug (Eylea) in EyePoint's failed trial; no direct impact on Regeneron disclosed in the article.
Major player in the atopic dermatitis market with significant operations in North America, benefiting from premium biologic therapy coverage and strong market growth projections.
Noted as the largest holding in PBE at 5.4%, but presented without specific performance commentary or recommendation.
Entered into strategic collaboration with Telix to jointly develop and commercialize next-generation radiopharmaceutical therapies focused on oncology. While this represents a positive partnership development, the article provides limited detail on Regeneron's specific benefits or financial impact, warranting a neutral stance from Regeneron's perspective.
Featured in the clinical-stage partnerships database as an active dealmaker, but the article provides no specific information about their individual deals or outcomes.
Specialist in monoclonal antibodies and biologics, well-positioned to benefit from market expansion driven by increased adoption of biologic therapies.
Strong sales growth (31% YoY in 2023, 22% YoY in Q2 2025), FDA approval for COPD expanding market opportunities, clinical superiority demonstrated over competitors, and diversification across multiple indications support continued revenue growth and market leadership.
Partnership with Alnylam on cemdisiran therapy in phase 3 trials for myasthenia gravis and paroxysmal nocturnal hemoglobinuria, but no specific performance metrics or developments disclosed.
Regeneron's Co-Founder and Chief Scientific Officer is featured as a keynote speaker, demonstrating leadership visibility and commitment to advancing drug delivery innovation.
Mentioned as a competitor to Apogee's APG279 drug through its Dupixent product. No direct impact from the acquisition is discussed, though increased competition in the immunology space is implied.
Strategic collaboration partner with Intellia for CRISPR-based therapies in neurological and muscular diseases. Partnership provides validation but is not the primary focus of the article's investment thesis.
Mentioned as a partnership collaborator on nex-z development for transthyretin amyloidosis, which addresses a larger patient population (250,000-500,000 worldwide). Partnership provides financial support and credibility but represents a minor component of Regeneron's overall portfolio.
Mentioned as a competitive threat to Ocular Therapeutix in the retinal disease space, representing larger pharmaceutical company competition but not directly evaluated in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
